Lebrikizumab: Phase II data

The double-blind Phase II MILLY trial in 218 patients with asthma inadequately controlled with inhaled corticosteroids showed that subcutaneous lebrikizumab met the primary endpoint of significantly improving the mean relative change in FEV1 from baseline to week

Read the full 370 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE